PSMA靶向放射性药物治疗联合免疫治疗
PSMA靶向放射性药物治疗是转移性去势抵抗性前列腺癌的标准治疗,β发射体[177Lu]Lu-PSMA-617于2022年获批并可延长无进展生存期和总生存期,但耐药和患者反应异质性限制疗效。本文综述将靶向放射性药物治疗与免疫检查点抑制剂(尤其PD-1和PD-L1抑制剂)联合的原理、临床前与临床证据及未来方向。
要点
- PSMA靶向放射性药物治疗利用PSMA过表达递送细胞毒性辐射,是转移性去势抵抗性前列腺癌的标准治疗。
- β发射体[177Lu]Lu-PSMA-617于2022年获批,与患者无进展生存期和总生存期延长相关。
- 将靶向放射性药物治疗与PD-1/PD-L1抑制剂联合可能增强抗肿瘤反应。
核心结论
- 将靶向放射性药物治疗与免疫检查点抑制剂(尤其PD-1和PD-L1抑制剂)联合可能增强抗肿瘤反应。
研究设计与样本
- 综述,探讨PSMA靶向放射性药物治疗联合免疫检查点阻断的原理,评估临床前与临床证据并讨论未来方向。
主要发现
- β发射体[177Lu]Lu-PSMA-617于2022年获批,与前列腺癌患者无进展生存期和总生存期延长相关。
- 耐药和患者反应异质性限制PSMA靶向放射性药物治疗的疗效。
- 前列腺癌的免疫抑制微环境常降低免疫治疗的效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PSMA-targeted radiopharmaceutical therapy (RPT) is a standard treatment for metastatic castration-resistant prostate cancer (PCa), exploiting PSMA overexpression to deliver cytotoxic radiation. Treatment with the β-emitter [177Lu]Lu-PSMA-617, approved in 2022, has been associated with prolonged progression-free and overall survival in patients with PCa. However, resistance and heterogeneous patient responses limit its efficacy. Although immunotherapy is effective in several malignancies, PCa's immunosuppressive microenvironment often reduces its impact. Combining targeted RPT with immune checkpoint inhibitors, particularly programmed cell death protein 1 and programmed cell death ligand 1 inhibitors, may enhance antitumor responses. This review explores the rationale behind this combination, evaluates preclinical and clinical evidence, and discusses future directions for integrating immune checkpoint blockade with targeted RPT.
引用
- Altunay B, Schäfer L, Morgenroth A, et al. Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy. J Nucl Med. 2025. PMID: 40876956. doi:10.2967/jnumed.125.270317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。